Product Categories

Cyclopamine

Catalog No.S1146

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Contact Us
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Tel:
(510) 833-3558 (Local Sales) | (832) 582-8158 (Houston Office)
[email protected]
Cyclopamine Chemical Structure

Cyclopamine Chemical Structure
Molecular Weight: 411.62

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Cyclopamine is available in the following compound libraries:

Inhibitor Library Bioactive Compound Library Stem Cell Signaling Compound Library Cambridge Cancer Compound Library

Hedgehog/Smoothened Inhibitors with Unique Features

  • Selective Smoothened inhibitor

    PF-5274857 Smoothened-selective, IC50=5.8 nM.

  • Smoothened Inhibitor in Clinical Trial

    LDE225 (NVP-LDE225,Erismodegib) Phase III for Hh-pathway activated relapsed Medulloblastoma (MB).

  • Newest Smoothened Inhibitor

    GANT61 Inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.

  • Smoothened Activator

    Purmorphamine Directly binds and activates Smoothened, and blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM.

Product Information

  • Compare Hedgehog/Smoothened Inhibitors
    Compare Hedgehog/Smoothened Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity Protocol Chemical Information FAQ Tech Support

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets Smoothened [1]
(TM3Hh12 cells)
IC50 46 nM
In vitro Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
OS-RC-2MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTaeW1KSzVyPUWuPFY3PiEQvF2=Mn7SV2FPT0WU
DOHH-2M33le2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXBTWM2OD17LkO1Olg6KM7:TR?=NIfoVGtUSU6JRWK=
no-10NGDKSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPHc5dKSzVyPUmuPVA{QSEQvF2=NIXUSJBUSU6JRWK=
LS-513NVzUO3BWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLkTWM2OD1zMT6zOVQ4KM7:TR?=M{\RVnNCVkeHUh?=
ALL-POM1H6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;3TWM2OD1zMT63O|M1KM7:TR?=NYjTV|NmW0GQR1XS
8-MG-BANWLKXpZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2L3eGlEPTB;MUOuNVEzOyEQvF2=NFLIVpFUSU6JRWK=
RPMI-8402MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7Gd4dKSzVyPUG1Mlg2OzdizszNM2jFSXNCVkeHUh?=
EoL-1-cellMlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTF6LkW5OFgh|ryPM1fRNHNCVkeHUh?=
NALM-6MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTF7LkCxOlch|ryPMoDjV2FPT0WU
DELM1fiVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmruTWM2OD1{MD6xOFcyKM7:TR?=MV7TRW5ITVJ?
SRMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTJ|Lk[3NVUh|ryPNIjNXnJUSU6JRWK=
697M{XLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jsfmlEPTB;Mk[uOlE2PSEQvF2=MmL0V2FPT0WU
COLO-829M4L1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7pT3RKSzVyPUK2Mlg1QDNizszNM2\5VHNCVkeHUh?=
EVSA-TNHHhc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPmPIdKSzVyPUK3MlU2PjFizszNMorFV2FPT0WU
ATN-1NHzJPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfCTWM2OD1|MT6yN|I6KM7:TR?=MXHTRW5ITVJ?
L-363NHPlRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HIe2lEPTB;M{GuO|Q3OSEQvF2=NX;xV3g6W0GQR1XS
LAMA-84NIfGTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XIfGlEPTB;M{KuOVIyOSEQvF2=M{j2OXNCVkeHUh?=
NOS-1M3v2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\EZ45jUUN3ME2zOE4zQTV4IN88US=>NHXEeIhUSU6JRWK=
BB30-HNCMnPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{S1UGlEPTB;M{SuN|MxPiEQvF2=NIXwS2pUSU6JRWK=
BC-1MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrlOIszUUN3ME2zO{46PzR4IN88US=>MnOxV2FPT0WU
IST-SL2M1X5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDDTWM2OD1|OD6yNlQh|ryPMU\TRW5ITVJ?
D-392MGM3H2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrZTWM2OD12MD6yNlE2KM7:TR?=MXnTRW5ITVJ?
no-11NX24WVl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTRyLkW1NlEh|ryPNV;kfpE3W0GQR1XS
LC4-1NEHNS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTRyLki3NVYh|ryPMUDTRW5ITVJ?
A388Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfhTWM2OD12Mj61PFQ5KM7:TR?=M3LQWHNCVkeHUh?=
NTERA-S-cl-D1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHXTWM2OD12Mj63NFc1KM7:TR?=MoS4V2FPT0WU
CESSM{HpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTNTWM2OD12ND6yNlMzKM7:TR?=MnLjV2FPT0WU
RS4-11M13WcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH2wRW1KSzVyPUS5MlA6OzhizszNMlLpV2FPT0WU
MS-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEL6N2JKSzVyPUWwMlk{PTFizszNMX3TRW5ITVJ?
CTV-1NIDGOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHFVnR5UUN3ME21NU4xPzRizszNMnq4V2FPT0WU
D-502MGMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHX3TXlKSzVyPUWxMlYzPzFizszNNXHSTVljW0GQR1XS
ML-2MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TBVmlEPTB;NUKuPVE6PSEQvF2=MmjjV2FPT0WU
SK-NEP-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;uPWlEPTB;NUOuN|kzOyEQvF2=NIiydopUSU6JRWK=
LOXIMVIM2q1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1S2WGlEPTB;NUOuOVg5PCEQvF2=NI[5N4lUSU6JRWK=
DJM-1M{D4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTV4LkOzPVEh|ryPNIm0fFlUSU6JRWK=
GI-1M4jRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEi2OZJKSzVyPUW2MlYyPDlizszNMXnTRW5ITVJ?
IST-MES1Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYK3flFCUUN3ME22NE42PDl|IN88US=>MXzTRW5ITVJ?
MV-4-11MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTZyLk[1N|gh|ryPMlmxV2FPT0WU
OVCAR-4MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTZ|LkW2OVch|ryPNVjhenc6W0GQR1XS
KE-37M{jnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;ucohKSzVyPU[2MlI3PjhizszNNGjTc4ZUSU6JRWK=
D-542MGNYTQc|ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\VemJZUUN3ME22PE41OTN3IN88US=>M2O0bXNCVkeHUh?=
MHH-PREB-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{Hqd2lEPTB;N{KuPFQ1OSEQvF2=MXXTRW5ITVJ?
MRK-nu-1NGTMO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\5c2lEPTB;N{OuOFcxPSEQvF2=MnraV2FPT0WU
D-247MGMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2KySmlEPTB;N{OuOVQ1OiEQvF2=M1eyfHNCVkeHUh?=
OCI-AML2M2Xv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTd4LkmzOlkh|ryPM4DSPHNCVkeHUh?=
LP-1M{nMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;JTWM2OD16Mj64O|MyKM7:TR?=M4HV[3NCVkeHUh?=
HCC1599M4jocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1frPWlEPTB;OESuNlg{PyEQvF2=NHnPRVVUSU6JRWK=
KARPAS-45Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\jemlEPTB;OESuOlk6OiEQvF2=NWTuUGtwW0GQR1XS
BE-13M13NZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTl7LkC0O|ch|ryPNFPiVldUSU6JRWK=
GCIYNWDGVnMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPwRo1KSzVyPUm5MlA6PTRizszNMY\TRW5ITVJ?
BV-173NH7NRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4r4XmlEPTB;MUCwMlMzPSEQvF2=Mn7qV2FPT0WU
LB2518-MELM{TWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTFyMD63PFkh|ryPNIXqeWZUSU6JRWK=
KS-1NXnI[ok2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;G[nlrUUN3ME2xNFEvPjN7IN88US=>NUXERmRHW0GQR1XS
MOLT-16M4DkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULXWm14UUN3ME2xNFQvQTh4IN88US=>MlzPV2FPT0WU
NCI-H1770NEjz[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXSTWM2OD1zMEiuO|g1KM7:TR?=NXvz[YhXW0GQR1XS
NCI-H82M13HVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTFzMD65O|Yh|ryPM{ftUXNCVkeHUh?=
NCCITNIrkeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDMfVNtUUN3ME2xNVIvPTJ7IN88US=>MXvTRW5ITVJ?
KALS-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEj2dm1KSzVyPUGxOU46PDFizszNNGW3Z4ZUSU6JRWK=
LB2241-RCCMnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPjTWM2OD1zMU[uOlc6KM7:TR?=MXPTRW5ITVJ?
HHNHLMb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLUW4lKSzVyPUGxO{4{QTVizszNNHPVWHpUSU6JRWK=
HD-MY-ZMlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vCemlEPTB;MUG4MlQ5QCEQvF2=NUfpdmliW0GQR1XS
EB-3NG\FZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTF{Mz6wPVQh|ryPM{jIXXNCVkeHUh?=
BL-70MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3myVWlEPTB;MUKzMlEzPyEQvF2=M3PaXXNCVkeHUh?=
K-562MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFj0PWtKSzVyPUGyOk4zPDVizszNNYDPbHBEW0GQR1XS
HT-144MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXv6OXREUUN3ME2xN|MvOTZ2IN88US=>Ml:yV2FPT0WU
PF-382Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLuVmJGUUN3ME2xN|QvOzZzIN88US=>MUfTRW5ITVJ?
RPMI-8226M1zZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrZfGFWUUN3ME2xN|UvODR3IN88US=>NWH4dJVRW0GQR1XS
NCI-H1355NGXoSIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnTTWM2OD1zM{WuOVg4KM7:TR?=MnP2V2FPT0WU
LXF-289NWjE[5VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfKTWM2OD1zM{muO|gyKM7:TR?=NH3v[JhUSU6JRWK=
NCI-H69NFfGdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjGbIVYUUN3ME2xOFIvQTN{IN88US=>MWDTRW5ITVJ?
SK-MEL-1M37Xcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfuTWM2OD1zNEeuNVMh|ryPNEjCVZlUSU6JRWK=
KARPAS-299NVXtU4hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmiyTWM2OD1zNEmuNVIh|ryPNGH2R2pUSU6JRWK=
GB-1M{ixUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnnc2pKSzVyPUG0PU4{OjJizszNMYjTRW5ITVJ?
CMKMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17YZmlEPTB;MUS5MlUyPSEQvF2=MWTTRW5ITVJ?
MPP-89M4DZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\rTWM2OD1zNU[uNFM2KM7:TR?=M3LvVXNCVkeHUh?=
KU812NGLy[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXLTI1KSzVyPUG2NU46ODJizszNMX;TRW5ITVJ?
REHMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jOcGlEPTB;MU[yMlEzPSEQvF2=MlnQV2FPT0WU
NEC8M4PiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTF4NT6wNlYh|ryPMXXTRW5ITVJ?
KP-N-YSNXX2fG5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWW4WYlWUUN3ME2xOlgvOzl3IN88US=>MXzTRW5ITVJ?
Ramos-2G6-4C10NVy2OpZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1O1c2lEPTB;MU[5MlkyPSEQvF2=NInpPFhUSU6JRWK=
BeckerMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILRN2JKSzVyPUG3OE4yQCEQvF2=NEXnTI1USU6JRWK=
LB647-SCLCNH3zVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfFTWM2OD1zN{WuPFQ2KM7:TR?=MUnTRW5ITVJ?
LU-139MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml20TWM2OD1zN{iuNFE6KM7:TR?=NYrrT2V{W0GQR1XS
QIMR-WILMlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTUbm0xUUN3ME2xO|kvPjR4IN88US=>MmfuV2FPT0WU
NCI-H1395MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\lSHdzUUN3ME2xO|kvQTl4IN88US=>NXTmT2VVW0GQR1XS
NOMO-1Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTNTWM2OD1zOEKuPFUh|ryPNFK1OGJUSU6JRWK=
GI-ME-NMnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIP3fmdKSzVyPUG4O{46PjlizszNNXrCPJpmW0GQR1XS
KMS-12-PEMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTF6OT6yO|Mh|ryPNYD3XJVLW0GQR1XS
DaudiM3zaO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXYbJJKSzVyPUG5NU4yOjhizszNMmfQV2FPT0WU
LB996-RCCNHS1d2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3DOmxFUUN3ME2xPVEvPjl7IN88US=>NEHqbJdUSU6JRWK=
NCI-H2107MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LKc2lEPTB;MUmzMlc{QSEQvF2=NESwSlRUSU6JRWK=
SK-PN-DWMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzjW5p2UUN3ME2xPVQvPzF7IN88US=>NX3WRZlmW0GQR1XS
MC-CARM3H1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTJyMj6yOVMh|ryPM3P2bXNCVkeHUh?=
SNB75M2Hj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHlN25vUUN3ME2yNlEvQTRizszNMW\TRW5ITVJ?
ES4NH\JVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TuN2lEPTB;MkKzMlc5OyEQvF2=NIrQblJUSU6JRWK=
KARPAS-422MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13OfWlEPTB;MkK4MlM2OiEQvF2=MXXTRW5ITVJ?
NCI-H1648M2LRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTJ{OT60PFkh|ryPNYW0[mh7W0GQR1XS
ES6NFL3clZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LSSWlEPTB;MkO5MlQ{KM7:TR?=M3fvW3NCVkeHUh?=
KNS-81-FDMlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFmzN|RKSzVyPUK0NU4yQTdizszNMoP5V2FPT0WU
JARM2nveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1WxSmlEPTB;MkW2MlIzPSEQvF2=M{S0UHNCVkeHUh?=
NB1NIXCNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfJU49KSzVyPUK2NE42OTZizszNNIDlfotUSU6JRWK=
D-336MGNGHRS41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVPWOYpwUUN3ME2yOlAvPjl6IN88US=>NE\wfo1USU6JRWK=
BC-3NHvMWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILOT5BKSzVyPUK2OU4yPzhizszNMnqzV2FPT0WU
HCC2218NUHNT|ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nwTmlEPTB;Mk[2MlQyPSEQvF2=M1zHOXNCVkeHUh?=
TE-9NX:2cXZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;MO5p[UUN3ME2yOlYvPjJ5IN88US=>MWHTRW5ITVJ?
LB1047-RCCM2P0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3np[GlEPTB;Mk[2Mlc2OyEQvF2=MoD3V2FPT0WU
CTB-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nleWlEPTB;Mk[5Mlk4OyEQvF2=M1vvNXNCVkeHUh?=
NB7M3LGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;CTWM2OD1{N{Gg{txONEPqUI9USU6JRWK=
ST486MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;JUmlEPTB;Mke3MlQyOiEQvF2=M{\GXHNCVkeHUh?=
HCC1187M{DDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLYeHpKSzVyPUK4Nk45OTFizszNMnLiV2FPT0WU
NCI-SNU-16M{ntSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3nTWM2OD1{OESuNlQ5KM7:TR?=MofFV2FPT0WU
COR-L279MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2OwXmlEPTB;MkmxMlU5PCEQvF2=MlzTV2FPT0WU
ES8MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTJ7ND6xPFIh|ryPMYDTRW5ITVJ?
U-698-MNYTUSGtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTaVHZJUUN3ME2yPVgvOjR|IN88US=>NYK2UG5HW0GQR1XS
HELNUfxWnVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlflTWM2OD1|MEmuNVQ6KM7:TR?=MWLTRW5ITVJ?
KINGS-1NFPLZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zjXmlEPTB;M{GwMlY4PCEQvF2=MlLDV2FPT0WU
KY821NXfrVHBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;BTWM2OD1|M{[uOVk2KM7:TR?=MlvpV2FPT0WU
MZ1-PCNXXsZWNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\EVGlEPTB;M{S1MlYyQCEQvF2=NHnifodUSU6JRWK=
LS-411NM1viZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjDZ3FKUUN3ME2zOVQvPjZizszNMUfTRW5ITVJ?
SIG-M5MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLJTW5KSzVyPUO1PU44QDJizszNNX7yeGtFW0GQR1XS
HTNYPreIZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXJUJdrUUN3ME2zOlcvPzFzIN88US=>NH:1dodUSU6JRWK=
HC-1NIH4R3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTN4Nz63PFch|ryPMoq4V2FPT0WU
NCI-H1694NIjl[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTN5Mj65N|Qh|ryPMXjTRW5ITVJ?
BB65-RCCMmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTN5Nj6yOFUh|ryPMVvTRW5ITVJ?
HAL-01NEX3WpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEGwOWhKSzVyPUO3PU45OzhizszNMWfTRW5ITVJ?
ARH-77NYjZfHRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvEPIZwUUN3ME2zPVQvODB6IN88US=>NH;vcIdUSU6JRWK=
MZ7-melNGf5Z5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDYOGdTUUN3ME2zPVcvOjN|IN88US=>MofmV2FPT0WU
SIMAMkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTRyMz65N|Mh|ryPNXm1em13W0GQR1XS
DG-75MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXQb2VKSzVyPUSxOU43QThizszNMnPRV2FPT0WU
HUTU-80M{XFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LO[2lEPTB;NEG5MlE5PSEQvF2=Mn;pV2FPT0WU
KNS-42MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTR{NT64NVUh|ryPMnWwV2FPT0WU
SH-4MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorxTWM2OD12MkeuOVY2KM7:TR?=NV3uVVRrW0GQR1XS
L-540NWPwR2h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTR|MT6wN|Eh|ryPNHfRSolUSU6JRWK=
NB10NHqxfXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXoSZBKSzVyPUS0NU4zOzRizszNMXnTRW5ITVJ?
ES1NH\rSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTR3Mj63OVMh|ryPNH:1enNUSU6JRWK=
KMOE-2MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWntTWR{UUN3ME20OVYvPzFzIN88US=>NYHEdpNZW0GQR1XS
MC116NYPwfWIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnJSWhTUUN3ME20OVgvOTF4IN88US=>MV7TRW5ITVJ?
RCC10RGBNFPFfpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjnRnl7UUN3ME20OlAvODB3IN88US=>MV7TRW5ITVJ?
RL95-2M4\1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTR4MD6yN|ch|ryPMnfOV2FPT0WU
RajiMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTR4OD6xOFMh|ryPMYLTRW5ITVJ?
CAS-1M{DWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrVPYZKSzVyPUS3Nk4xPzNizszNMVzTRW5ITVJ?
Calu-6MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTR5NT6yOlUh|ryPMX7TRW5ITVJ?
KG-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;kTWM2OD12N{iuOFQh|ryPNVj5TpFKW0GQR1XS
LB771-HNCM2H4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHuTWM2OD12OEKuNlMzKM7:TR?=NH7q[IhUSU6JRWK=
ACNNG\MdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3u1R2lEPTB;NEmzMlU6QSEQvF2=NWi1WlRmW0GQR1XS
KM12MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\NUJhWUUN3ME20PVYvPTh7IN88US=>NFj6OIJUSU6JRWK=

... Click to View More Cell Line Experimental Data
In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Hedgehog cell assay This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack

Cell Assay: [2]

Cell lines SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
Concentrations Dissolved in DMSO, final concentration 3 μM
Incubation Time 4 days
Method Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).

Animal Study: [2]

Animal Models Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
Formulation Dissolved in DMSO, and diluted in saline
Dosages 50 mg/kg/day
Administration Subcutaneous injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Peukert S, et al. Bioorg Med Chem Lett, 2009, 19(2), 328-331.

[2] Berman DM, et al. Nature, 2003, 425(6960), 846-851.

view more

Chemical Information

Download Cyclopamine SDF
Molecular Weight (MW) 411.62
Formula

C27H41NO2
CAS No. 4449-51-8
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms 11-deoxojervine
Solubility (25°C) * In vitro DMF 10 mg/mL warming (24.29 mM)
Ethanol 2 mg/mL warming (4.85 mM)
Water <1 mg/mL (<1 mM)
In vivo 10% DMSO+30% PEG 300+5% Tween 80+ddH2O 1mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name Spiro[9H-benzo[a]fluorene-9,2'(3'H)-furo[3,2-b]pyridin]-3-ol, 1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11,11a,11b-octadecahydro-3',6',10,11b-tetramethyl-, (2'R,3S,3'R,3'aS,6'S,6aS,6bS,7'aR,11aS,11bR)-
Molarity Calculator Dilution Calculator Molecular Weight Calculator

Customers Who Bought This Item Also Bought

  • Smoothened Agonist (SAG) HCl

    Smoothened Agonist (SAG) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells.

  • LDE225 (NVP-LDE225,Erismodegib)

    LDE225 (NVP-LDE225,Erismodegib) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays, respectively. Phase 3.

  • Purmorphamine

    Purmorphamine, which directly binds and activates Smoothened, blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM in HEK293T cell and also is an inducer of osteoblast differentiation with EC50 of 1 μM.

  • Olaparib (AZD2281, Ku-0059436)

    Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Phase 3.

    Features:A potent PARP inhibitor (currently in late stage clinical trials).

  • Vismodegib (GDC-0449)

    Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.

  • Y-27632 2HCl

    Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions
Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Hedgehog/Smoothened Products

  • Smoothened Agonist (SAG) HCl

    Smoothened Agonist (SAG) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells.

  • SB225002

    SB225002 is a potent, and selective CXCR2 antagonist with IC50 of 22 nM for inhibiting interleukin IL-8 binding to CXCR2, > 150-fold selectivity over the other 7-TMRs tested.

  • SB-334867

    SB-334867 is a selective orexin-1 (OX1) receptor antagonist.

  • Vismodegib (GDC-0449)

    Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.

  • GANT61

    GANT61 is an inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM in GLI1 expressing HEK293T cell, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.

  • Purmorphamine

    Purmorphamine, which directly binds and activates Smoothened, blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM in HEK293T cell and also is an inducer of osteoblast differentiation with EC50 of 1 μM.

  • LDE225 (NVP-LDE225,Erismodegib)

    LDE225 (NVP-LDE225,Erismodegib) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays, respectively. Phase 3.

  • Taladegib (LY2940680)

    Taladegib (LY2940680) binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling. Phase 1/2.

  • Glasdegib (PF-04449913)

    Glasdegib (PF-04449913) is a potent, and orally bioavailable Smoothened (Smo) inhibitor with IC50 of 5 nM. Phase 2.

  • SANT-1

    SANT-1 directly binds to Smoothened (Smo) receptor with Kd of 1.2 nM and inhibits Smo agonist effects with IC50 of 20 nM.

    Features:Attenuates SAG stimulation of Shh-LIGHT2 cells to a greater extent relative to other antagonists.

Recently Viewed Items

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us